Bio Vantage
Contributor since: 2012
Company: Biovantage Investments
Latest Articles
Gilead's 12-month Price Target At $84
Johnson & Johnson's 12-month Price Target At $105
Biogen Idec: Financial Projections And Stock Valuation, Part 2
Biogen Idec 5-Year Revenue Outlook
Gilead Financial Projection And Stock Valuation, Part 2
Gilead Five-year Revenue Outlook, Part 1
Acadia Stock Report: Stock Valuation
Acadia Stock Report: Business Overview And Revenue Projection
Amgen's Onyx Acquisition Will Add $14 To Its Stock Value
Expedited Drug Approval May Push Up Pharmacyclics' Value And Stock Price
Is Amgen's $120 Offer For Onyx Too Low? - Part 3
Onyx Pharmaceuticals 5-Year Revenue Projection - Part 2
Incyte: Financial Projection And Stock Valuation
Onyx Pharmaceuticals Rejected Amgen's $120 Per Share Acquiring Offer - Part 1
3 Sources Of Revenue For Incyte
How Much Should You Pay For Incyte?
Will Generic Competitors Of Enbrel Affect Amgen's Stock Price?
Novartis: Financial Projection And Stock Valuation
Novartis: Drug Pipeline And New Drug Applications
Novartis: 5-Year Revenue Outlook
Our Model Suggests An Intrinsic Value Of $117 For Amgen
Four Factors Driving Amgen's Stock Price To $102
What Is Johnson & Johnson's Fair Value After Invokana Approval?
How Much Will FDA Action On Invokana Affect Johnson & Johnson's Revenue And Stock Price?
Is Pfizer Overvalued At $28.5?
Pharmacyclics, Part 4: Financial Projection And Stock Valuation
Pharmacyclics, Part 3: Financials And Its Partnership With Johnson And Johnson
Pharmacyclics, Part 2: How Much Revenue Could Ibrutinib Generate?
Pharmacyclics, Part 1: Can The Incredible Run Continue?
Pfizer: Financial Projection And Stock Valuation
How Much Will Pfizer's New Drugs Contribute To Future Revenue?
What Does Pfizer's 2012 Earnings Tell Us About Its Operations?